This Duke Consortia for HIV/AIDS Vaccine Development (CHAVD) funded in 2019 will apply state-of-the-art technologies and immunologic tools to focus on iterative, rational vaccine design that within seven years will lead to a successful final vaccine design. There were two consortiums funded, one at Duke University and one at Scripps Research Institute.
The Duke CHAVD will build on 14 years of experience in the Duke Center for HIV/AIDS Vaccine Immunology and the Duke CHAVI-ID programs.
Why has an HIV vaccine been so difficult to develop over the past 35 years? Learn about the challenges and major milestones from a phase 1 clinical trial.
The Duke Human Vaccine Institute develops a vaccine that triggers elusive antibodies against HIV